ARO-AAT
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alpha 1-Antitrypsin Deficiency
Conditions
Alpha 1-Antitrypsin Deficiency
Trial Timeline
Oct 31, 2019 → Dec 14, 2023
NCT ID
NCT03946449About ARO-AAT
ARO-AAT is a phase 2 stage product being developed by Arrowhead Pharmaceuticals for Alpha 1-Antitrypsin Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT03946449. Target conditions include Alpha 1-Antitrypsin Deficiency.
What happened to similar drugs?
2 of 9 similar drugs in Alpha 1-Antitrypsin Deficiency were approved
Approved (2) Terminated (0) Active (7)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03946449 | Phase 2 | Completed |
Competing Products
20 competing products in Alpha 1-Antitrypsin Deficiency